Agios Pharmaceuticals, Inc. (AGIO) | Stock price, performance, AI analysis | Thematic | AI powered fundamental research and development platform

Loading...

Research a topic Stock screener Find companies

Search for securities Load an existing portfolio Backtest

Thematic overview Develop asset-backed products Company evaluations Backtesting and benchmarking Thematic branded indices

Research a topic Stock screener Find companies

Search for securities Load an existing portfolio Backtest

Thematic overview Develop asset-backed products Company evaluations Backtesting and benchmarking Thematic branded indices

Follow our journey and product updates

Product

Overview Company evaluations Research a topic

Company

About us Blog Contact

Legal

Terms Privacy Policy

Agios Pharmaceuticals, Inc. (AGIO)

Evaluation: Based on all recent filings, financial statements, and news.

See full evaluation

Ask a question about Agios Pharmaceuticals, Inc. (AGIO)

Company Performance

Current Price

as of Dec 03, 2024

$58.88

P/E Ratio

5.18

Market Cap

$3.36B

Description

Agios Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in a research engine, multiple novels, and investigational therapies in preclinical development. It focuses on cellular metabolism and classical hematology. The company was founded by Lewis Clayton Cantley, Tak W. Mak, Craig B. Thompson and Shin-Shan Michael Su on August 7, 2007 and is headquartered in Cambridge, MA.

Metrics

Overview

HQCambridge, MA
SectorHealth Technology
IndustryPharmaceuticals: Major
TickerAGIO
Price$58.88+0.02%

Trading Information

Market cap$3.36B
Float96.68%
Average Daily Volume (1m)720,889
Average Daily Volume (3m)577,845
EPS$11.79

Company

Revenue$32.87M
Rev growth (1yr)21.15%
Net income$947.92M
Gross margin76.26%
EBITDA margin-1,131.93%
EBITDA-$101.47M

EV$1.65B
EV/Revenue50.26
P/E5.18
P/S104.67
P/B2.06

Documents

SEC Filings

8-K (2024-10-31)

8-K (2024-08-01)

8-K (2024-06-20)

8-K (2024-05-28)

8-K (2024-05-02)

8-K (2024-02-15)

8-K (2024-01-08)

8-K (2023-11-02)

8-K (2023-08-03)

8-K (2023-06-14)

8-K (2023-05-25)

8-K (2023-05-04)

8-K (2023-04-19)

8-K (2023-03-03)

8-K (2023-02-23)

8-K (2023-01-09)

10-Q (2024-10-31)

10-Q (2024-08-01)

10-Q (2024-05-02)

10-Q (2023-11-02)

10-Q (2023-08-03)

10-Q (2023-05-04)

10-K (2024-02-15)

10-K (2023-02-23)

Wikipedia

Agios_Pharmaceuticals

Factset Street Account

StreetAccount Earnings Call Q&A Summary: Agios Pharmaceuticals Q3 ($ 21.41, +0.11) (2023-11-02T15:28:44Z)

Servier (private) issues press release on previously reported FDA approval of TIBSOVO for r/r MDS ($20.97, +0.01) (2023-10-24T19:36:05Z)

FDA approves sNDA for Tibsovo (ivosidenib) to treat myelodysplastic syndromes (MDS) ($20.87, -0.09) (2023-10-24T18:30:15Z)

Agios Pharmaceuticals to present Broad Set of clinical and translational data in rare blood disorders at 65th ASH Annual Meeting and Exposition ($21.30, 0.00) (2023-11-02T13:17:53Z)

Agios Pharmaceuticals reports Q3 EPS ($1.64) vs FactSet ($1.70) [8 est, ($1.95)-(1.51)] ($21.30, 0.00) (2023-11-02T11:02:04Z)

Agios Pharmaceuticals announces clinical proof-of-concept in Phase 2a trial of AG-946 for the treatment of Anemia in lower-risk myelodysplastic syndromes ($22.26, 0.00) (2023-11-20T12:02:12Z)

Earnings Calls

Earnings Report 2024Q3

Earnings Report 2024Q2

Earnings Report 2024Q1

Earnings Report (2023-11-02)

Earnings Report (2023-08-03)

Factset

Factset Business Description